Form 4: Rhythm Pharmaceuticals Director Camille L. Bedrosian Reports Stock Unit Vesting
SEC Form 4 Filing
Director Camille L. Bedrosian reports the vesting of 3,000 restricted stock units into common stock of Rhythm Pharmaceuticals.
Summary
- On June 21, 2024, Camille L. Bedrosian, a director of Rhythm Pharmaceuticals, had 3,000 restricted stock units vest.
- These units converted into 3,000 shares of Rhythm Pharmaceuticals common stock.
- The transaction was reported on June 25, 2024.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting routine compensation practices. It doesn't inherently signal positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The vesting of stock units may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Restricted stock units fully vested and converted to common stock. |
| 06/25/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.